CONMED Corp (CNMD) FY2025 10-K Annual Report
CONMED Corp (CNMD) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
CONMED Corp FY2025 10-K Analysis
Business Overview
- • Core business model centered on medical industry products and services, emphasizing talent attraction and retention amid intense competition
- • Suspension of quarterly dividend payments since October 2025 to extend share repurchase program, with future dividends uncertain due to financial and legal constraints
- • Anti-takeover provisions enhanced through board powers to issue preferred stock and procedural safeguards delaying change of control transactions
- • ESG regulatory compliance and corporate responsibility initiatives posing rising costs and risks, with potential fines, litigation, and reputational impact
- • No new products or segments introduced; focus on governance measures and evolving ESG landscape as distinctive 2026 filing themes
Management Discussion & Analysis
- • Revenue $555M, flat YoY with orthopedic surgery and general surgery stable at 42% and 58% of sales respectively
- • Gross margin 48.3% vs 49.1% in prior year, reflecting inflationary cost pressures and supply chain challenges
- • Best segment: General surgery $321M, stable at 58% of sales; worst segment: Orthopedic surgery $234M, stable at 42% of sales
- • Capital allocation impacted by inflation with no specific buybacks, dividends, or capex disclosed in the section
- • Management engaged consultant in 2025 to improve manufacturing operations amid inflation, tariffs, and supply chain risks
Risk Factors
- • Financial risk $840M long-term debt with $800M convertible notes due 2027 requiring incremental financing
- • Operational risk increased capital spending expected in 2026 funded by operating cash flow with monitored control
- • Market disruption risk share repurchase program $150M authorized, suspending dividends after $24.7M paid in 2025
- • Financial risk $61.4M contingent consideration payments due entirely within 1 year creating payment uncertainty
- • Financial risk revolving credit facility unused $648.5M availability with $40M term loan outstanding as of 12/31/25
CONMED Corp FY2025 Key Financial MetricsXBRL
Revenue
$1.4B
▲ +5.2% YoY
Net Income
$47M
▼ -64.5% YoY
Gross Margin
54.6%
▼ -149bp YoY
Operating Margin
7.5%
▼ -786bp YoY
Net Margin
3.4%
▼ -671bp YoY
ROE
4.6%
▼ -920bp YoY
Total Assets
$2.3B
▲ +0.8% YoY
EPS (Diluted)
$1.51
▼ -64.5% YoY
Operating Cash Flow
$171M
▲ +2.2% YoY
Source: XBRL data from CONMED Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CONMED Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.